Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.65 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19231182 | 0.84 | SIGMAR1 (0.64) | SIGMAR1CTSSTDP2TMEM97AOC3 | |
| SCHEMBL22095095 | 0.79 | SIGMAR1 (1.00) | SIGMAR1CTSSTMEM97 | |
| SCHEMBL6969973 | 0.79 | NR1H3 (0.58) | SIGMAR1TMEM97 | |
| SCHEMBL27216894 | 0.76 | SIGMAR1 (0.55) | SIGMAR1CTSSTDP2 | |
| SCHEMBL17803244 | 0.76 | SIGMAR1 (0.55) | SIGMAR1CTSSTMEM97AOC3 | |
| SCHEMBL17803359 | 0.74 | CTSS (0.48) | SIGMAR1CTSSTDP2 | |
| SCHEMBL17803226 | 0.73 | TDP2 (0.50) | SIGMAR1CTSSTDP2AOC3 | |
| Hydrochloric Acid SCHEMBL28846665 | 0.73 | CTSS (0.47) | SIGMAR1CTSSTDP2 | |
| SCHEMBL13239882 | 0.73 | PTGS2 (0.45) | SIGMAR1 | |
| SCHEMBL13239883 | 0.72 | MALT1 (0.44) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001332-B | Piperidine derivatives | 豪夫迈·罗氏有限公司 | 2020-05-15 | — | — | CN | disclosed |
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-10-10 | — | — | US | disclosed |
| EP-3227282-B1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-03 | — | — | EP | disclosed |
| EP-3227282-B1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-03 | — | — | EP | disclosed |
| US-10172843-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172843-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3227282-A1 | NOVEL PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-09-21 | — | — | US | disclosed |
| CN-107001332-A | New piperidine derivative | 豪夫迈·罗氏有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2016087352-A1 | NOVEL PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087352-A1 | NOVEL PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | ADORA1, ADRA1D, ADORA2B | SIGMAR1 30/4885CTSS 2891/4885TDP2 2636/4885 |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | ADORA1, ADRA1D, ADORA2B | SIGMAR1 30/4885CTSS 2891/4885TDP2 2636/4885 |
| US-10172843-B2 | Piperidine derivatives | ADRA1D, ADORA1, ADRA1A | SIGMAR1 62/4885CTSS 2938/4885TDP2 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.